GPCR structural studies with in-solution spectroscopic approaches have offered distinctive insights into GPCR activation and signaling that highly complement those yielded from structural snapshots by crystallography or cryo-EM. While most current spectroscopic approaches allow for probing structural changes at selected residues or loop regions, they are not suitable for capturing a holistic view of GPCR conformational rearrangements across multiple domains. Herein, we develop an approach based on limited proteolysis mass spectrometry (LiP-MS) to simultaneously monitor conformational alterations of a large number of residues spanning both flexible loops and structured transmembrane domains for a given GPCR. To benchmark LiP-MS for GPCR conformational profiling, we studied adenosine 2A receptor (A2AR) in response to different ligand binding (agonist/antagonist/allosteric modulators) and G protein coupling. Systematic and residue-resolved profiling of A2AR conformational rearrangements by LiP-MS precisely captures structural mechanisms in multiple domains underlying ligand engagement, receptor activation and allostery, and may also reflect local conformational flexibility. Furthermore, these residue-resolution structural fingerprints of A2AR protein allow us to readily classify ligands of different pharmacology and distinguish the G protein-coupled state. Thus, we establish a new structural MS approach that would help address ligand or transducer-induced conformational transition and plasticity, a long-standing challenge for GPCR biology and rational drug design.
Auf unserem Internetauftritt verwenden wir Cookies. Bei Cookies handelt es sich um kleine (Text-)Dateien, die auf Ihrem Endgerät (z.B. Smartphone, Notebook, Tablet, PC) angelegt und gespeichert werden. Einige dieser Cookies sind technisch notwendig um die Webseite zu betreiben, andere Cookies dienen dazu die Funktionalität der Webseite zu erweitern oder zu Marketingzwecken. Abgesehen von den technisch notwendigen Cookies, steht es Ihnen frei Cookies beim Besuch unserer Webseite zuzulassen oder nicht.